Clinical InvestigationAcute Ischemic Heart DiseaseThe triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: A Report From the Women's Ischemia Syndrome Evaluation (WISE)
Section snippets
Study population
The Women's Ischemia Syndrome Evaluation (WISE) study is a National Heart, Lung, and Blood Institute–sponsored 4-center prospective cohort study designed to improve the diagnostic reliability of cardiovascular testing in the evaluation of ischemic heart disease in women. Between 1996 and 2000, 936 women (out of 7,603 screened and 1,903 found eligible) ≥18 years presenting to study sites for clinically indicated coronary angiography to evaluate suspected myocardial ischemia were enrolled. Major
Baseline characteristics
The average age was 57 ± 11 years, 16% of women were African American, 55% had a history of hypertension, 20% were diabetic, and 50% had a history of smoking. The mean TG/HDL-C ratio with TG and HDL-C expressed in milligrams per deciliter (corresponding values expressed in millimoles per liter in parentheses) was 2.9 ± 2.2 (1.3 ± 0.96); median, 2.2 (0.96); range, 0.3 to 18.4 (0.13-8.0) (Figure 1).
Table I summarizes baseline characteristics by TG/HDL-C quartile. Age was similar across quartiles.
Discussion
To our knowledge, this is the first study among high-risk women to show that the TG/HDL-C ratio is a powerful predictor of total mortality independent of important prognostic variables including age, race, smoking, hypertension, diabetes, and severity of coronary artery disease. We also found a strong relationship between the TG/HDL-C ratio and severity of coronary artery disease as well as subsequent cardiovascular events among these women with suspected myocardial ischemia.
Correlates of high
Conclusion
Among high-risk women under evaluation for myocardial ischemia, the TG/HDL-C ratio is a powerful independent predictor of cardiovascular events and all-cause mortality. Clinical trials targeting the abnormal TG/HDL-C ratio in such women appear to be warranted.
Disclosures
Dr. Bairey-Merz has consulted for and/or received lecture fees from Novartis (East Hanover, NJ), CMP Media (Manhasset, NY), Rodale Press (New York, NY), Adventist Health (Roseville, CA), Bayer AG (Leverkusen, Germany), CV Therapeutics (Palo Alto, CA), Remillard and Associates (Honolulu, HI) Navigant Consulting (Chicago, IL), Hunt and Associates (Honolulu, HI), Pfizer (New York, NY). Dr. Bairey-Merz also has stock ownership in Boston Scientific (Natick, MA), Eli Lilly (Indianapolis, IN),
References (26)
Perspectives on dyslipidemia and coronary heart disease in women
J Am Coll Cardiol
(2005)- et al.
Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster Study
Am J Cardiol
(1992) - et al.
The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein–depleted plasma (FERHDL)
Clinical Biochemistry
(2001) - et al.
Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B
Am J Cardiol
(2004) - et al.
Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?
Am J Cardiol
(2005) - et al.
Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study angiographic core laboratory
Am J Cardiol
(2001) - et al.
Heart Disease and Stroke Statistics — 2008 Update
Circulation
(2008) - et al.
Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies
J Cardiovasc Risk
(1996) - et al.
Triglycerides and the risk of coronary heart disease. 10 158 Incident cases among 262 525 participants in 29 western prospective studies
Circulation
(2007) - et al.
Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement
Circulation
(2005)
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment
Circulation
Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S
Circulation
Relationship between total cholesterol/high-density lipoprotein cholesterol ratio, triglyceride/high-density lipoprotein cholesterol ratio, and high-density lipoprotein subclasses
Metabolism
Cited by (0)
Funding sources: This work was supported by contracts from the National Heart, Lung and Blood Institutes, nos. N01-HV-68161, N01-HV-68162, N01-HV-68163, N01-HV-68164; grants U0164829, U01 HL649141, U01 HL649241, GCRC grant MO1-RR00425 from the National Center for Research Resources; and grants from the Gustavus and Louis Pfeiffer Research Foundation (Denville, NJ), The Women's Guild of Cedars-Sinai Medical Center (Los Angeles, CA), The Ladies Hospital Aid Society of Western Pennsylvania (Pittsburgh, PA), and The Edythe Broad Endowment for Women's Heart Research (Los Angeles, CA).